Efficacy of Concanavalin-A conjugated nanotransfersomal gel of apigenin for enhanced targeted delivery of UV induced skin malignant melanoma
Source abstract
Abstract
The aim of present study was to develop the efficient targeting of Concanavalin-A conjugated nanotransfersomal gel to bind directly to melanocytes gel layer against UVB induced skin carcinoma. Carbopol loaded nanotransfersomal gel have prepared by modified rotary evaporation sonication technique & conjugated synthesized by carbodiimide method and they were characterized the morphology, zeta potential, penetration and cell viability. In vitro release studies & skin permeation have determined using Franz diffusion cell and confocal laser scanning microscope (CLSM). The conjugated formulation showed vesicles size, polydispersity index, zeta potential and % conjugation efficiency of 179.0 ± 0.32 nm, 0.197 ± 0.07, 35.1 ± 0.21 mV and 89.73 ± 1.29% respectively. The surface morphology was confirmed by transmission electron microscopy (TEM) and FTIR to make sure the compatibility among its ingredients. Con-A conjugated nanotransfersomal gel showed toxicity on melanoma (A375) in a concentration range of 0.4-2.0 mg/mL, but less toxicity toward HaCaT cells. The MTT assay has analyzed against two different cell lines, to determine their anti-cancer potentials and their targeting ability. Conjugated formulation were found to decrease the cell viability, higher skin targeting efficacy in in-vitro & in-vivo. Concanavalin conjugated nanotransfersomal gel of apigenin promise an efficient and economic approach for the skin cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Essential Oils and Antimicrobial Activity · Flavonoids in Medical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
University Institute of Pharmacy, Pt. Ravishankar Shukla University
Shri Rawatpura Sarkar Institute of Pharmacy
References (47)
Show source-provided references
1. Kwona K, Hanb B, Parka K et al. Analysis on the current status of targeted drug delivery to tumours. J Control Release. 2012;164(2):1–18.
2. Kamboj S, Saini V, Bala S, et al. Vesicular drug delivery systems: a novel approach for drug targeting. Int J Drug Deliv. 2013;5(2):121–130.
3. 10.1016/j.nano.2014.11.00610.1016/j.nano.2014.11.006 ↗
4. 10.1007/s40204-017-0064-z10.1007/s40204-017-0064-z ↗
5. 10.3934/molsci.2017.1.110.3934/molsci.2017.1.1 ↗
6. 10.1007/s12079-009-0084-010.1007/s12079-009-0084-0 ↗
7. 10.4161/auto.428010.4161/auto.4280 ↗
8. 10.4161/auto.5.3.792410.4161/auto.5.3.7924 ↗
9. 10.1038/aps.2013.15110.1038/aps.2013.151 ↗
10. 10.18433/J3830G10.18433/J3830G ↗
11. Rai S, Pandey V, Rai G. Transfersomes as versatile and flexible nanovesicular carriers in skin cancer therapy: the state of the art. Drug Deliv. 2017;8:1–18.
12. 10.1080/10717544.2016.122871810.1080/10717544.2016.1228718 ↗
13. 10.2174/187484810090201007110.2174/1874848100902010071 ↗
14. 10.1080/21691401.2016.124785010.1080/21691401.2016.1247850 ↗
15. 10.1080/03639045.2017.131385710.1080/03639045.2017.1313857 ↗
16. 10.1166/jnn.2015.1033310.1166/jnn.2015.10333 ↗
17. Yan X, Zhan Y, Shao H, et al. Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. Cell Biosci. 2017;7(50):1–16.
18. 10.15430/JCP.2016.21.4.21610.15430/JCP.2016.21.4.216 ↗
19. 10.3892/or.2017.545010.3892/or.2017.5450 ↗
20. 10.3892/ijo.2015.324310.3892/ijo.2015.3243 ↗
21. 10.1186/s13045-016-0373-z10.1186/s13045-016-0373-z ↗
22. 10.3892/ol.2016.433110.3892/ol.2016.4331 ↗
23. 10.1016/j.jddst.2015.09.00710.1016/j.jddst.2015.09.007 ↗
24. 10.1016/j.nano.2017.12.00110.1016/j.nano.2017.12.001 ↗
25. 10.1016/j.ejpb.2016.04.02310.1016/j.ejpb.2016.04.023 ↗
26. 10.1021/acsbiomaterials.6b0068110.1021/acsbiomaterials.6b00681 ↗
27. 10.1016/j.jconrel.2009.10.01610.1016/j.jconrel.2009.10.016 ↗
28. 10.1016/j.ijpharm.2016.06.13610.1016/j.ijpharm.2016.06.136 ↗
29. 10.1081/DDC-12002545810.1081/DDC-120025458 ↗
30. 10.1080/10717544.2017.134433310.1080/10717544.2017.1344333 ↗
31. 10.1158/0008-5472.CAN-05-307710.1158/0008-5472.CAN-05-3077 ↗
32. Gupta A, Kaur CD, Saraf S. Formulation, characterization, and evaluation of ligand-conjugated biodegradable quercetin nanoparticles for active targeting. Artif Cells Nanomed Biotechnol. 2016;44(3):1–11.
33. 10.1016/S0005-2736(97)00177-610.1016/S0005-2736(97)00177-6 ↗
34. Abdallah MH Transfersomes as a transdermal drug delivery system for enhancement the antifungal activity of Nystatin. Int J Pharm Sci. 2013;5(4):560–567.
35. 10.1016/0142-9612(96)81413-X10.1016/0142-9612(96)81413-X ↗
36. 10.1021/mp800193n10.1021/mp800193n ↗
37. 10.3109/10717544.2014.90214610.3109/10717544.2014.902146 ↗
38. 10.7815/ijorcs.11.2011.00610.7815/ijorcs.11.2011.006 ↗
39. 10.1590/s1984-8250201600030001510.1590/s1984-82502016000300015 ↗
40. Garg T, Goyal AK, Marwah A, et al. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv. 2015;23(2):564–578.
41. 10.1016/S0169-409X(01)00112-010.1016/S0169-409X(01)00112-0 ↗
42. 10.1016/j.ijpharm.2013.11.01710.1016/j.ijpharm.2013.11.017 ↗
43. 10.1016/j.fct.2013.09.03710.1016/j.fct.2013.09.037 ↗
44. 10.1080/10717544.2016.126782110.1080/10717544.2016.1267821 ↗
45. Mukerje A, Vishwanatha JK. Characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29:3867–3876.
46. 10.1016/j.nano.2011.06.00410.1016/j.nano.2011.06.004 ↗
47. Sarwa KK, Rudrapal M, Mazumder B. Topical ethosomal capsaicin attenuates edema and nociception in arthritic rats. Drug Deliv. 2013;22:1–10.